Psychopharmacology
-
Upload
saira-nawaz -
Category
Health & Medicine
-
view
9 -
download
6
description
Transcript of Psychopharmacology
![Page 1: Psychopharmacology](https://reader031.fdocuments.us/reader031/viewer/2022013011/545592b2af7959d2368b6ac6/html5/thumbnails/1.jpg)
Vernon Rosario, MD, PhDAssociate Clinical Professor
Dept. of Psychiatry and Biobehavioral Sciences
![Page 2: Psychopharmacology](https://reader031.fdocuments.us/reader031/viewer/2022013011/545592b2af7959d2368b6ac6/html5/thumbnails/2.jpg)
Overview
• Neurotransmission & pharmacodynamics• Pharmacokinetics• Some medications affecting the brain and
behavior:o antipsychoticso mood stabilizerso antidepressantso antianxiety medicationso stimulants
Adapted from Steven A. Fink, PhD, Jarred von Snellenberg, PhD, Heidi Combs & MD Shamim Nejad, MD
![Page 3: Psychopharmacology](https://reader031.fdocuments.us/reader031/viewer/2022013011/545592b2af7959d2368b6ac6/html5/thumbnails/3.jpg)
Synaptic Transmission:Action Potentials
http://videosift.com/video/Brain-Synapses-and-Neurotransmission-3D-Animation
![Page 4: Psychopharmacology](https://reader031.fdocuments.us/reader031/viewer/2022013011/545592b2af7959d2368b6ac6/html5/thumbnails/4.jpg)
Pharamacodynamics:Where Drugs Act
• Four sites of actiono Receptors (those sites to which a
neurotransmitter can specifically adhere to produce a change in the cell membranes)
o Ion channelso Enzymeso Carrier Proteins
• Biologic action depends on how its structure interacts with a receptor
![Page 5: Psychopharmacology](https://reader031.fdocuments.us/reader031/viewer/2022013011/545592b2af7959d2368b6ac6/html5/thumbnails/5.jpg)
Receptors• Types of Action
o Agonist: same biologic actiono Antagonist: opposite effect
• Interactions with a receptor o Selectivity: specific for a receptoro Affinity: degree of attractiono Intrinsic activity: ability to produce a biologic
response once it is attached to receptor
![Page 6: Psychopharmacology](https://reader031.fdocuments.us/reader031/viewer/2022013011/545592b2af7959d2368b6ac6/html5/thumbnails/6.jpg)
Ion Channels
• Drugs can block or open the ion channels
• Example: benzodiazepine drugs facilitate GABA in opening the chloride ion channel
Potassium channel. Image Source Page: http://www.beckman.illinois.edu/news/Illinoisgating
![Page 7: Psychopharmacology](https://reader031.fdocuments.us/reader031/viewer/2022013011/545592b2af7959d2368b6ac6/html5/thumbnails/7.jpg)
Enzymes
• Enzymes catalyze specific biochemical reactions within cells and are targets for some drugs
• Monoamine oxidase is an enzyme that breaks down most bioamine neurotransmitters (NE, DA, 5-HT)
• Enzymes may be inhibited to produce greater neurotransmitter effect.
![Page 8: Psychopharmacology](https://reader031.fdocuments.us/reader031/viewer/2022013011/545592b2af7959d2368b6ac6/html5/thumbnails/8.jpg)
Carrier Proteins
• Transport neurotransmitters across cell membranes
• Medications may block or inhibit this transport
• Example: antidepressants (SSRI) on serotonin transporter protein
Image Source Page: http://scientopia.org/blogs/scicurious/2010/08/25/back-to-basics-3-depression-post-6/
![Page 9: Psychopharmacology](https://reader031.fdocuments.us/reader031/viewer/2022013011/545592b2af7959d2368b6ac6/html5/thumbnails/9.jpg)
Efficacy and Potency• Efficacy - Ability of a drug to produce a response
as a result of the receptor or receptors being occupied.
• Potency - Dose required to produce the desired biologic response.
• Loss of effect o desensitization (rapid decrease in drug effect)o tolerance (gradual decrease in the effect of a drug at
a given dose)o can lead to patient being treatment refractory
![Page 10: Psychopharmacology](https://reader031.fdocuments.us/reader031/viewer/2022013011/545592b2af7959d2368b6ac6/html5/thumbnails/10.jpg)
Target Symptoms and Side Effects• Target symptoms
Specific symptoms treated for each class of medication
• Side effects Responses (+ or -) not related to target symptoms
• Adverse drug reaction Unwanted effects with serious physiologic
consequences.
![Page 11: Psychopharmacology](https://reader031.fdocuments.us/reader031/viewer/2022013011/545592b2af7959d2368b6ac6/html5/thumbnails/11.jpg)
Drug Toxicity• Toxicity
Point at which concentration of the drug in the blood stream becomes harmful or poisonous to the body.
• Image Source Page: http://www.beltina.org/health-dictionary/narrow-therapeutic-index-nti.html
![Page 12: Psychopharmacology](https://reader031.fdocuments.us/reader031/viewer/2022013011/545592b2af7959d2368b6ac6/html5/thumbnails/12.jpg)
Drug Toxicity• Therapeutic index
Ratio of the dose that produces toxicity in 50% to the dose that is therapeutically effective in 50%
• TD50/ED50 High therapeutic index: wide range between dose at which the
drug begins to take effect and dose that would be considered toxic
Low therapeutic index: low range
Image Source Page: http://quizlet.com/5151182/usmle-pharmacology-principles-flash-cards/
![Page 13: Psychopharmacology](https://reader031.fdocuments.us/reader031/viewer/2022013011/545592b2af7959d2368b6ac6/html5/thumbnails/13.jpg)
Pharmacokinetics:How the Body Acts on the Drug
• Absorption
• Distribution
• Metabolism
• Elimination
![Page 14: Psychopharmacology](https://reader031.fdocuments.us/reader031/viewer/2022013011/545592b2af7959d2368b6ac6/html5/thumbnails/14.jpg)
Pharmacokinetics
Blood BrainBarrier
P450 Enzymes
J van Snellenberg 2007
![Page 15: Psychopharmacology](https://reader031.fdocuments.us/reader031/viewer/2022013011/545592b2af7959d2368b6ac6/html5/thumbnails/15.jpg)
Absorption• From site of administration into the plasma• Oral - (tablet and liquid)
o Most Conveniento Most variable (food and antacids)
First pass effect Decreased gastric motility (age, disease, medication)
• IM - Short-and long acting• IV - Rarely used outside hospital
![Page 16: Psychopharmacology](https://reader031.fdocuments.us/reader031/viewer/2022013011/545592b2af7959d2368b6ac6/html5/thumbnails/16.jpg)
Bioavailability
• Amount of drug that reaches systemic circulation unchanged
• Often used to compare one drug to another, usually the higher the bioavailability, the better
![Page 17: Psychopharmacology](https://reader031.fdocuments.us/reader031/viewer/2022013011/545592b2af7959d2368b6ac6/html5/thumbnails/17.jpg)
Distribution• Amount of drug found in various tissues,
especially the intended ones • Psychiatric drugs must pass through blood-brain
barrier (most fat-soluble)• Factors effecting distribution
o Size of organ (larger requires more)o Blood flow (more, greater concentration)o Solubility (greater, more concentration)o Plasma protein (if bound, slower distribution, stays in body longer)o Anatomic barriers (tissues surrounding)
![Page 18: Psychopharmacology](https://reader031.fdocuments.us/reader031/viewer/2022013011/545592b2af7959d2368b6ac6/html5/thumbnails/18.jpg)
Crossing the Blood Brain Barrier• Passive diffusion
o Drug must dissolve in the structure of the cello Lipid solubility is necessary for drugs passing through
blood brain barrier (then, can also pass through placenta)
• Binding to other moleculeso Plasma protein binding o The more protein binding, the less drug activity.o Can bind to other cells, especially fat cells. Then are
released when blood level decreases.
Image Source Page: http://www.nanowerk.com/spotlight/spotid=19339.php
![Page 19: Psychopharmacology](https://reader031.fdocuments.us/reader031/viewer/2022013011/545592b2af7959d2368b6ac6/html5/thumbnails/19.jpg)
Metabolism
• Process by which the drug is altered and broken down into smaller substances (metabolites) that are usually inactive.
• Lipid-soluble drugs become more water soluble, so they may be more readily excreted.
• Most metabolism is carried out in the liver
![Page 20: Psychopharmacology](https://reader031.fdocuments.us/reader031/viewer/2022013011/545592b2af7959d2368b6ac6/html5/thumbnails/20.jpg)
Cytochrome P450 (CYP)
Largest class of enzymes catalyzing oxidation of organic substances in all living things • 11,550+ identified ; 57 in humans• High affinity for fat-soluble drugs• Involved in metabolism of most psychiatric medications• Inactivate drugs (or in some cases activate them)• Chemicals may increase or decrease CYP activity• Example:
o SSRIs inhibitors of the subfamily CYP2D6o Compounds in grapefruit juice inhibit CYP3A4o Tobacco induces CYP1A2
![Page 21: Psychopharmacology](https://reader031.fdocuments.us/reader031/viewer/2022013011/545592b2af7959d2368b6ac6/html5/thumbnails/21.jpg)
Elimination• Clearance: Total amount of blood, serum, or
plasma from which a drug is completely removed per unit time
• Half-life: Time required for plasma concentrations of the drug to be reduced by 50%
• Only a few drugs eliminated by kidneys (lithium)• Most excreted via the liver
o excreted in the bile and delivered to the intestineo may be reabsorbed in intestine and “re-circulate” (up
to 20%)
![Page 22: Psychopharmacology](https://reader031.fdocuments.us/reader031/viewer/2022013011/545592b2af7959d2368b6ac6/html5/thumbnails/22.jpg)
Dosing and Steady State
• Dosing: Administration of medication over time, so that therapeutic levels can be achieved.
• Steady-state: o drug accumulates and plateaus
at a particular level o rate of accumulation
determined by half lifeo reach steady state in about five
times the elimination half-life
![Page 23: Psychopharmacology](https://reader031.fdocuments.us/reader031/viewer/2022013011/545592b2af7959d2368b6ac6/html5/thumbnails/23.jpg)
Pharmacokinetics: Ethnicity
• 9% of whites - genetically defective CYP2D6• Asian descent
o Metabolize ethanol to produce higher concentrations of acetaldehyde (flushing, palpitations)
o Require 1/2 to 1/3 dose antipsychotics and have more severe side effects
• Cardiovascular effects of propranololo Asian descent - more sensitiveo African descent - less sensitive
![Page 24: Psychopharmacology](https://reader031.fdocuments.us/reader031/viewer/2022013011/545592b2af7959d2368b6ac6/html5/thumbnails/24.jpg)
Phases of Drug Treatment• Initiation• Stabilization• Maintenance• Discontinuation
![Page 25: Psychopharmacology](https://reader031.fdocuments.us/reader031/viewer/2022013011/545592b2af7959d2368b6ac6/html5/thumbnails/25.jpg)
Psychiatric Medications• Antipsychotic Medications• Movement Disorders Medication• Mood Stabilizers
o Antimanico Antidepressant
• Antianxiety and Sedative-Hypnotic• Stimulants
![Page 26: Psychopharmacology](https://reader031.fdocuments.us/reader031/viewer/2022013011/545592b2af7959d2368b6ac6/html5/thumbnails/26.jpg)
Antipsychotic Medications
• Target symptoms: psychosis• Types
o Conventionalo Atypical
• Absorption: variableo clinical effects seen 30-60 mino IM less variable (avoid 1st pass)o when immobile, less absorption of IM
• Metabolism: liver• Excretion: slow
o accumulates in fatty tissueso 1/2 life of 24 hours or more
![Page 27: Psychopharmacology](https://reader031.fdocuments.us/reader031/viewer/2022013011/545592b2af7959d2368b6ac6/html5/thumbnails/27.jpg)
Antipsychotic Medications• Preparations
o Oralo IMo Depot - haloperidol and fluphenazine
• Side Effectso Cardiovascular: orthostatic hypotensiono Weight-gain: blocking histamine receptoro Endocrine and sexual: block dopamine, interfere with
prolactino Blood dyscrasias: agranulocytosis
![Page 28: Psychopharmacology](https://reader031.fdocuments.us/reader031/viewer/2022013011/545592b2af7959d2368b6ac6/html5/thumbnails/28.jpg)
Antipsychotic Medications
• Conventionalo Phenothiazines (Thorazine, Prolixin)o Thioxanthenes (Navane)o Dibenzoxazepines (Loxitane)o Haloperidol (Haldol)
• Atypical or Novelo Clozapine (Clozaril)o Risperidone (Risperdal)o Olanzapine (Zyprexa)o Quetiapine (Seroquel)o Ziprasidone (Geodon)o Aripiprazole (Abilify)o Asenapine (Saphris)o Iloperidone (Fanapt)o Lurasidone (Latuda)o Paliperidone (Invega)
![Page 29: Psychopharmacology](https://reader031.fdocuments.us/reader031/viewer/2022013011/545592b2af7959d2368b6ac6/html5/thumbnails/29.jpg)
Antipsychotic Side Effects• Cardiovascular: arrhythmia, incr. heart rate
• Anticholinergic: dry mouth, dry eyes, imbalance, pupil dilatation, double vision, constipation, confusion, delirium
• Weight Gain• Endocrine: hyperprolactinemia > milk production, irregular periods,
hyperthermia, diabetes
• Blood Disorders: decr. white blood count
• Miscellaneous: jaundice, rash, photosensitivity
![Page 30: Psychopharmacology](https://reader031.fdocuments.us/reader031/viewer/2022013011/545592b2af7959d2368b6ac6/html5/thumbnails/30.jpg)
Medication-Related Movement Disorders: Acute Syndromes
• Can occur in 90% of all patients• Dystonia: involuntary muscle spasms, abnormal
postures, oculogyric crisis, torticollis• Parkinsonism: rigidity, akinesia (slow movement),
and tremor, masklike face, loss of spontaneous movements
• Akathisia: Inability to sit still, restlessness• Extrapyramidal Symptoms (EPS) (11 min)
![Page 31: Psychopharmacology](https://reader031.fdocuments.us/reader031/viewer/2022013011/545592b2af7959d2368b6ac6/html5/thumbnails/31.jpg)
Movement Disorders: Acute (cont.)• Etiology (acute):
o Related to dopamine in nigrostrial pathway that increases cholinergic activity
• Treatmento Anticholinergic medication for dystonia, parkinsonism
(Artane and Cogentin)o Akathisia does not usually respond to anticholinergic
medication. Beta blockers have best success.
![Page 32: Psychopharmacology](https://reader031.fdocuments.us/reader031/viewer/2022013011/545592b2af7959d2368b6ac6/html5/thumbnails/32.jpg)
Movement Disorders: Chronic• Tardive Dyskinesia
o Irregular, repetitive involuntary movements of mouth, face, and tongue, including chewing, tongue protrusion, lip smacking, puckering of the lips, and rapid eye blinking. Abnormal finger movements are common. More common in women and elderly.
• Symptomso Begin after 6 months, but also as antipsychotics are
withdrawno Irreversible - controversy
![Page 33: Psychopharmacology](https://reader031.fdocuments.us/reader031/viewer/2022013011/545592b2af7959d2368b6ac6/html5/thumbnails/33.jpg)
Movement Disorders: Chronic• Etiology
o believed that chronic dopamine suppression in the EPS causes an overactivation of the system
o increases in antipsychotic meds, suppresses• Treatment
o prevention by using lowest possible dosage, minimize use of PRN, closely monitor individuals in high-risk groups
o monitoring tools
![Page 34: Psychopharmacology](https://reader031.fdocuments.us/reader031/viewer/2022013011/545592b2af7959d2368b6ac6/html5/thumbnails/34.jpg)
Mood Stabilizers: AntimaniaLithium Carbonate• Action: uncertain, crosses cell membranes,
altering sodium transport, not protein bound• Side Effects: thirst, metallic taste, increased
frequency or urination, fine head and hand tremor, drowsiness, and mild diarrhea
• Blood levels monitored (lithium toxicity - severe diarrhea, vomiting, drowsiness, muscular weakness, and lack of coordination, withhold)
![Page 35: Psychopharmacology](https://reader031.fdocuments.us/reader031/viewer/2022013011/545592b2af7959d2368b6ac6/html5/thumbnails/35.jpg)
Lithium Carbonate• Monitor creatinine concentrations, thyroid
hormones, and CBC every 6 months. • Kidney damage may be a risk• Thyroid function may be altered usually after 6-
18 months. Observe for dry skin, constipation, bradycardia, hair loss, cold intolerance
• Avoid during pregnancy (associated with cardiac defects and arrhythmia)
![Page 36: Psychopharmacology](https://reader031.fdocuments.us/reader031/viewer/2022013011/545592b2af7959d2368b6ac6/html5/thumbnails/36.jpg)
Mood Stabilizers: Antimania Anticonvulsants• Valporate and derivatives (divalproex sodium -
Depakote)• Carbamazapine (Tegretol)• Gabapentin (Neurontin) (least side effects)• Lamotrigine (Lamictal)• Topiramate (Topamax)
• Highly protein bound• Metabolized by the cytochrome P450 system• Side effects: dizziness, drowsiness, tremor, visual disturbance,
nausea, & vomiting
![Page 37: Psychopharmacology](https://reader031.fdocuments.us/reader031/viewer/2022013011/545592b2af7959d2368b6ac6/html5/thumbnails/37.jpg)
Anticonvulsant Mood Stabilizers• Only carbamazepine is approved for mania.• Used when patients have not responded to lithium• Pharmacokinetics
o Highly protein bound, metabolized by P450 system (potential drug-drug interaction)
![Page 38: Psychopharmacology](https://reader031.fdocuments.us/reader031/viewer/2022013011/545592b2af7959d2368b6ac6/html5/thumbnails/38.jpg)
CarbamazepineSide Effects
• Dizziness, drowsiness, tremor, visual disturbances, nausea, and vomiting
• Minimized by treating in low doses• Give with food• Weight gain• Alopecia (hair loss)
![Page 39: Psychopharmacology](https://reader031.fdocuments.us/reader031/viewer/2022013011/545592b2af7959d2368b6ac6/html5/thumbnails/39.jpg)
Antidepressants Tricyclic: Tertiary Amines
• Amitriptyline (Elavil)• Clomipramine (Anafranil)• Doxepine (Sinequan)• Imipramine (Tofranil)• Trimipramine (Surmontil)
![Page 40: Psychopharmacology](https://reader031.fdocuments.us/reader031/viewer/2022013011/545592b2af7959d2368b6ac6/html5/thumbnails/40.jpg)
Antidepressants:Secondary Amines
• Amoxapine (Asendin)• Desipramine (Norpramin)• Nortriptyline (Aventyl, Pamelor)• Protrypyline (Vivactil)
![Page 41: Psychopharmacology](https://reader031.fdocuments.us/reader031/viewer/2022013011/545592b2af7959d2368b6ac6/html5/thumbnails/41.jpg)
TCAs: Side Effects• Most common uncomfortable side effects
o sedationo orthostatic hypotensiono anticholinergic
• Otherso tremors, o restlessness, insomnia, confusiono pedal edema, headache, and seizureso blood dyscrasiaso sexual dysfunction
• Adverseo cardiotoxicity
![Page 42: Psychopharmacology](https://reader031.fdocuments.us/reader031/viewer/2022013011/545592b2af7959d2368b6ac6/html5/thumbnails/42.jpg)
Antidepressants• Most antidepressants block the re-uptake of a
neurotransmitter of one or more of the bioamines: serotonin, norepinephrine, dopamine
• SSRIs = Selective Serotonin Reuptake Inhibitors
![Page 43: Psychopharmacology](https://reader031.fdocuments.us/reader031/viewer/2022013011/545592b2af7959d2368b6ac6/html5/thumbnails/43.jpg)
Selective Serotonin Reuptake Inhibitors (SSRI)
• Fluoxetine (Prozac)• Sertraline (Zoloft)• Paroxetine (Paxil)• Fluvoxamine (Luvox)• Citalopram (Celexa)• Escitalopram (Lexapro)
![Page 44: Psychopharmacology](https://reader031.fdocuments.us/reader031/viewer/2022013011/545592b2af7959d2368b6ac6/html5/thumbnails/44.jpg)
SSRI: Side Effects• Headache• Anxiety• Transient nausea• Vomiting• Diarrhea• Weight gain• Sexual dysfunction
![Page 45: Psychopharmacology](https://reader031.fdocuments.us/reader031/viewer/2022013011/545592b2af7959d2368b6ac6/html5/thumbnails/45.jpg)
SSRIs• Usually given in morning, unless sedation occurs• Higher doses, especially paroxetine, can produce
sedation• Paroxetine associated with weight gain
![Page 46: Psychopharmacology](https://reader031.fdocuments.us/reader031/viewer/2022013011/545592b2af7959d2368b6ac6/html5/thumbnails/46.jpg)
Antidepressants: Monoamine Oxidase Inhibitors (MAOIs)
• Action: Inhibit enzyme responsible for the metabolism of serotonin, dopamine, norepinephrine, and tyramine.
• Increases levels of norepinephrine and serontonin in the CNS
• Interacts with food -- low tyramine diet (no cheese, liver, fermented or cured foods)
![Page 47: Psychopharmacology](https://reader031.fdocuments.us/reader031/viewer/2022013011/545592b2af7959d2368b6ac6/html5/thumbnails/47.jpg)
Antidepressants Others
• Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs)o Venlafaxine (Effexor)o Desvenlafaxine (Pristiq)o Duloxetine (Cymbalta)
• Mirtazapine (Remeron)• Trazodone (Desyrel)• Nefazodone (Serzone withdrawn due to rare liver failure)• Bupropion (Wellbutrin)
![Page 48: Psychopharmacology](https://reader031.fdocuments.us/reader031/viewer/2022013011/545592b2af7959d2368b6ac6/html5/thumbnails/48.jpg)
Antianxiety and Sedative-Hypnotic Medication• Used for anxiety, not long-term• Benzodiazepines
o diazepam (Valium)o lorazepam (Ativan)o alprazolam (Xanax)
• Nonbenzodiazepineso busipirone (BuSpar)o zolpidem (Ambien)
• Side effectso Sedation and CNS depressiono Tolerance and dependence (benzos)o Avoid benzos in children & elderly
![Page 49: Psychopharmacology](https://reader031.fdocuments.us/reader031/viewer/2022013011/545592b2af7959d2368b6ac6/html5/thumbnails/49.jpg)
Psychostimulants
• This class of drugs, in low to moderate doses, generally have the following effectso Heightened mood (euphoria)o Increase vigilance and alertnesso Reduce fatigueo Alertness
• In order of prevalence of useo Caffeineo Nicotineo Amphetamines/Cocaine
![Page 50: Psychopharmacology](https://reader031.fdocuments.us/reader031/viewer/2022013011/545592b2af7959d2368b6ac6/html5/thumbnails/50.jpg)
Psychostimulants
• Amphetamine, etc (cont.)o Low to moderate doses
Facilitate performance on sustained attention tasks, and those requiring physical quickness or strength
Especially if fatigued (Benzedrine used extensively in WW II) Increased energy, concentration, alertness, self-confidence, and
mood Social interactions may be enhanced Suppresses appetite
o High doses generally interfere with performance Also can lead to dysphoria, social withdrawal, and depression
![Page 51: Psychopharmacology](https://reader031.fdocuments.us/reader031/viewer/2022013011/545592b2af7959d2368b6ac6/html5/thumbnails/51.jpg)
Psychostimulants
• Amphetamine, etc (cont.)o Extremely high doses or chronic use can lead to amphetamine-
induced psychosis Almost indistinguishable from paranoid schizophrenia
o Simple movements are often repeated for long periods E.g. continuous chewing, teeth grinding, tongue movement
o Chronic use leads to marked tolerance and, in chronic users, the administration of very high doses
![Page 52: Psychopharmacology](https://reader031.fdocuments.us/reader031/viewer/2022013011/545592b2af7959d2368b6ac6/html5/thumbnails/52.jpg)